Zevalin (ibritumomab tiuxetan)

DRUG2 trials

Sponsors

Biogen, University of Bologna

Conditions

Follicular LymphomaNon-Hodgkin's Lymphoma

Phase 2

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy

CompletedNCT00859001

University of BolognaFollicular Lymphoma

Updated: 2009-03-12

Phase 3

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

TerminatedNCT00057343

BiogenNon-Hodgkin's Lymphoma

Start: 2003-03-31Target: 400Updated: 2006-09-12